Mintage Journal of Pharmaceutical and Medical Sciences (ISSN: 2320-3315)

Author(s): AZHAR A. F. IBRAHIM1, ISA S. TOUHALI*1,HAIDERN. DAWOOD

Objective: The    study  were  to:  Determine    the    possible  implication of  Pneumocystis  jirovecii    in  a  sample  of    immunocompromised  Iraqi  patients  and  determine    the  prevalence  of    Dihydropteroate  synthase gene    related  to  treatment and  prophylaxis  failures. Methods:This  study  included  a  total of  two hundred  (n=200)clinical samples from  100  immunocompromised patients as  70  Bronchoalveolar  lavage  ,  21sputum  samples and 9  pleural fluids,  with underlying   different  diseases. Control group  included 100  samples(50  Bronchoalveolar  lavage,  30  sputum  samples  and  20  pleural  fluids) from  immunocompetent  individuals  from  immunocompetent  individuals  were  collected from of in-and out patients who attended of  Medical AL-Imammian AL-Kadhmain City teaching Hospital / Baghdad, Baghdad teaching Hospital / Baghdad, Al-Zahra teaching Hospital / Wasit province and other private Laboratories, during the period from May-2014 to March-2015. The detection pneumocystosis by molecular methods. Result:The organism was detected in bronchoalveolar lavage, and/or sputum of immunocompromised patients only. The highest detection rate was observed for the mtLSUrRNA gene in 19  (19%)  samples,  15  (15%)    of  these  samples    of  immunocompromised  patients  consist  of  DHPS  genes.  Conclusion:Pneumocystis  jirovecii,  is  the  fundamental opportunistic infection among immunocompromised patients.  The primers target  of  mtLSUrRNA has the most specific and sensitive for the detection of P. jirovecii. In the present study showed the  DHPS  gene  has served as a selective drug linked with sulfa resistance and PCR amplification target.